141 related articles for article (PubMed ID: 38057916)
21. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
22. Discrepancies between ALK protein disruption and occurrence of
Grenda A; Jarosz B; Krawczyk P; Kucharczyk T; Wojas-Krawczyk K; Reszka K; Krukowska K; Nicoś M; Pankowski J; Bryl M; Ramlau R; Kuźnar-Kamińska B; Grodzki T; Szczęsna A; Siemiątkowska K; Szumiło J; Batura-Gabryel H; Palonka M; Milanowski J
J Thorac Dis; 2018 Aug; 10(8):4994-5009. PubMed ID: 30233874
[TBL] [Abstract][Full Text] [Related]
23. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
[TBL] [Abstract][Full Text] [Related]
24. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.
Liao BC; Lin CC; Shih JY; Yang JC
Ther Adv Med Oncol; 2015 Sep; 7(5):274-90. PubMed ID: 26327925
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
26. Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan.
Maraqa B; Al-Ashhab M; Sughayer MA
J Int Med Res; 2022 Jun; 50(6):3000605221104181. PubMed ID: 35689392
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
[TBL] [Abstract][Full Text] [Related]
28. The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement.
Bilgin B; Şendur MAN; Yücel Ş; Hizal M; Güner G; Akyürek N; Erol C; Akıncı MB; Dede DŞ; Yalçın B; Kılıçkap S
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2637-2643. PubMed ID: 33528638
[TBL] [Abstract][Full Text] [Related]
29. STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report.
Feng C; Zhou R; Liu F; Wang T; Liu S; Shao Y
Front Oncol; 2021; 11():700341. PubMed ID: 34490099
[TBL] [Abstract][Full Text] [Related]
30. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
[TBL] [Abstract][Full Text] [Related]
31. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.
Guérin A; Sasane M; Zhang J; Macalalad AR; Galebach P; Jarvis J; Kageleiry A; Culver K; Wu EQ; Wakelee H
Cancer Epidemiol; 2015 Jun; 39(3):307-12. PubMed ID: 25914136
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.
Zhang YG; Jin ML; Li L; Zhao HY; Zeng X; Jiang L; Wei P; Diao XL; Li X; Cao Q; Tian XX
PLoS One; 2013; 8(5):e64821. PubMed ID: 23741400
[TBL] [Abstract][Full Text] [Related]
34. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement.
Fu S; Wang HY; Wang F; Huang MY; Deng L; Zhang X; Ye ZL; Shao JY
Chin J Cancer; 2015 Aug; 34(9):404-12. PubMed ID: 26253541
[TBL] [Abstract][Full Text] [Related]
36. Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report.
Wu X; Zhou H; He Z; Zhang Z; Feng W; Zhao J; Chen H; Wang S; Wang W; Wang Q
Transl Lung Cancer Res; 2020 Dec; 9(6):2494-2499. PubMed ID: 33489809
[TBL] [Abstract][Full Text] [Related]
37. Development of a novel ALK rearrangement screening test for non-small cell lung cancers.
Chen YL; Chen WL; Cheng YC; Lin MC; Yang SC; Tsai HW; Lin CC; Su WC; Chow NH; Ho CL
PLoS One; 2021; 16(9):e0257152. PubMed ID: 34559836
[TBL] [Abstract][Full Text] [Related]
38. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
39. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
40. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
